The ACMD has been busy: correspondence to government includes Ganaxolone: ACMD advice, Zuranolone: ACMD advice and Somapacitan, lonapegsomatropin and somatrogon: ACMD advice. Its Open call for evidence – Ketamine harms assessment will close on 19 August.


